Realigned transsulfuration drives BRAF-V600E-targeted therapy resistance in melanomaKlaudia Borbényi-Galambos, Péter Nagy, Tamás Ditrói et al.|Cell Metabolism|2025Cited by 19
Evolving Acquired Vemurafenib Resistance in a BRAF V600E Mutant Melanoma PDTX Model to Reveal New Potential TargetsJózsef Tóvári, Mihály Cserepes|Cells|2023Cited by 10